Hurel Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
8
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$2.48M
Hurel General Information
Description
Developer of advanced micro-liver tissue designed to focus on microfluidic cell-based assay platforms. The company's micro-liver tissue offers metabolic competency and endurance of cell culture that helps to simulate pharmacokinetic interactions among multiple tissues and organs, enabling physicians to endure for much longer time periods than traditional hepatic systems.
Contact Information
Website
www.hurelcorp.comCorporate Office
- North Brunswick Township, NJ
- United States
Corporate Office
- North Brunswick Township, NJ
- United States
Hurel Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 15-Sep-2021 | $2.48M | Completed | Generating Revenue | ||
| 6. Later Stage VC | 29-Jun-2018 | Cancelled | Generating Revenue | |||
| 5. Later Stage VC (Series A3) | 24-Sep-2014 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 27-Jun-2013 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series A) | 03-Apr-2013 | Completed | Generating Revenue | |||
| 2. Seed Round | Completed | Startup | ||||
| 1. University Spin-Out | 01-Jan-2006 | Completed | Startup |
Hurel Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A4 | ||||||||
| Series A3 | ||||||||
| Series A2 | 2,380,440 | $0.000100 | 10% | $0.7 | $0.7 | 1x | $0.7 | 7.68% |
| Series A1 | 5,860,673 | $0.000100 | 10% | $0.71 | $0.71 | 1x | $0.71 | 18.91% |
Hurel Patents
Hurel Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3271451-A1 | Methods for characterizing time-based hepatotoxicity | Inactive | 20-Mar-2015 | ||
| EP-3271451-A4 | Methods for characterizing time-based hepatotoxicity | Inactive | 20-Mar-2015 | ||
| US-20180113119-A1 | Methods for characterizing time-based hepatotoxicity | Inactive | 20-Mar-2015 | ||
| WO-2016154145-A1 | Methods for characterizing time-based hepatotoxicity | Inactive | 20-Mar-2015 | ||
| AU-2015312066-A1 | In vitro biliary excretion assay | Inactive | 02-Sep-2014 | G01N33/5091 |
Hurel Signals
Hurel Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Athena Capital Partners (Beverly Hills) | Venture Capital | Minority | ||
| Cornell University | University | |||
| Angel (individual) | Minority | |||
| Johnston Associates | Venture Capital | Minority | ||
| Spring Mountain Capital | Growth/Expansion | Minority |
Hurel FAQs
-
When was Hurel founded?
Hurel was founded in 2006.
-
Where is Hurel headquartered?
Hurel is headquartered in North Brunswick Township, NJ.
-
What is the size of Hurel?
Hurel has 8 total employees.
-
What industry is Hurel in?
Hurel’s primary industry is Discovery Tools (Healthcare).
-
Is Hurel a private or public company?
Hurel is a Private company.
-
What is the current valuation of Hurel?
The current valuation of Hurel is .
-
What is Hurel’s current revenue?
The current revenue for Hurel is .
-
How much funding has Hurel raised over time?
Hurel has raised $10M.
-
Who are Hurel’s investors?
Athena Capital Partners (Beverly Hills), Cornell University, , Johnston Associates, and Spring Mountain Capital are 5 of 7 investors who have invested in Hurel.
-
When was Hurel acquired?
Hurel was acquired on 15-Sep-2021.
-
Who acquired Hurel?
Hurel was acquired by BICO Group.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process